Cargando…
Fixed drug eruption after the Sinopharm COVID‐19 vaccine
After coronavirus disease 2019 (COVID‐19) became widespread around the world, several vaccines have been developed with variable efficacy and potency and based on different platforms to control the pandemic. One of these vaccines is Sinopharm (BBIBP‐CorV), which is an inactivated virus that was rele...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349928/ http://dx.doi.org/10.1002/jvc2.40 |
_version_ | 1784762163913555968 |
---|---|
author | Rekabi, Mahsa Sadati, Elham Mirzaei, Jamal Pourdowlat, Guitti Velayati, Ali Akbar Honarpisheh, Parisa |
author_facet | Rekabi, Mahsa Sadati, Elham Mirzaei, Jamal Pourdowlat, Guitti Velayati, Ali Akbar Honarpisheh, Parisa |
author_sort | Rekabi, Mahsa |
collection | PubMed |
description | After coronavirus disease 2019 (COVID‐19) became widespread around the world, several vaccines have been developed with variable efficacy and potency and based on different platforms to control the pandemic. One of these vaccines is Sinopharm (BBIBP‐CorV), which is an inactivated virus that was released by Sinopharm's Beijing institute in the summer of 2020. The most commonly reported side effects of the Sinopharm vaccine have included pain at the injection site, muscle pain, headache and fatigue. Dermatological reactions are also reported as less common and were mainly local injection site reactions. Fixed drug eruption (FDE) is a rare and unusual adverse effect and accounts for less than 1% of all severe acute respiratory syndrome coronavirus 2 vaccine‐related cutaneous manifestations. FDE has not been reported following the COVID‐19 inactivated vaccine. Here, we describe a rare case of FDE following the administration of the first shot of the Sinopharm vaccine. |
format | Online Article Text |
id | pubmed-9349928 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93499282022-08-04 Fixed drug eruption after the Sinopharm COVID‐19 vaccine Rekabi, Mahsa Sadati, Elham Mirzaei, Jamal Pourdowlat, Guitti Velayati, Ali Akbar Honarpisheh, Parisa JEADV Clinical Practice Case Reports After coronavirus disease 2019 (COVID‐19) became widespread around the world, several vaccines have been developed with variable efficacy and potency and based on different platforms to control the pandemic. One of these vaccines is Sinopharm (BBIBP‐CorV), which is an inactivated virus that was released by Sinopharm's Beijing institute in the summer of 2020. The most commonly reported side effects of the Sinopharm vaccine have included pain at the injection site, muscle pain, headache and fatigue. Dermatological reactions are also reported as less common and were mainly local injection site reactions. Fixed drug eruption (FDE) is a rare and unusual adverse effect and accounts for less than 1% of all severe acute respiratory syndrome coronavirus 2 vaccine‐related cutaneous manifestations. FDE has not been reported following the COVID‐19 inactivated vaccine. Here, we describe a rare case of FDE following the administration of the first shot of the Sinopharm vaccine. John Wiley and Sons Inc. 2022-06-29 /pmc/articles/PMC9349928/ http://dx.doi.org/10.1002/jvc2.40 Text en © 2022 The Authors. JEADV Clinical Practice published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Reports Rekabi, Mahsa Sadati, Elham Mirzaei, Jamal Pourdowlat, Guitti Velayati, Ali Akbar Honarpisheh, Parisa Fixed drug eruption after the Sinopharm COVID‐19 vaccine |
title | Fixed drug eruption after the Sinopharm COVID‐19 vaccine |
title_full | Fixed drug eruption after the Sinopharm COVID‐19 vaccine |
title_fullStr | Fixed drug eruption after the Sinopharm COVID‐19 vaccine |
title_full_unstemmed | Fixed drug eruption after the Sinopharm COVID‐19 vaccine |
title_short | Fixed drug eruption after the Sinopharm COVID‐19 vaccine |
title_sort | fixed drug eruption after the sinopharm covid‐19 vaccine |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349928/ http://dx.doi.org/10.1002/jvc2.40 |
work_keys_str_mv | AT rekabimahsa fixeddrugeruptionafterthesinopharmcovid19vaccine AT sadatielham fixeddrugeruptionafterthesinopharmcovid19vaccine AT mirzaeijamal fixeddrugeruptionafterthesinopharmcovid19vaccine AT pourdowlatguitti fixeddrugeruptionafterthesinopharmcovid19vaccine AT velayatialiakbar fixeddrugeruptionafterthesinopharmcovid19vaccine AT honarpishehparisa fixeddrugeruptionafterthesinopharmcovid19vaccine |